argenx SE (“argenx” or the “Company”) is a commercial-stage, global, fully-integrated biotechnology company developing a deep pipeline of differentiated therapies for the treatment of severe autoimmune diseases. The Company focuses on neuromuscular, hematology, dermatology and nephrology indications within its franchises. On December 17, 2021, the U.S. Food and Drug Administration approved efgartigimod, which is being marketed as VYVGART™ (efgartigimod alfa-fcab), for the treatment of generalized myasthenia gravis, or gMG, in adult patients who are acetylcholine receptor antibody positive. On January 20, 2022, the Japan Pharmaceuticals and Medical Devices Agency approved VYVGART™ (efgartigimod alfa) for the treatment of adult patients with gMG who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies. With these regulatory milestones, VYVGART™ is the first-and-only approved neonatal Fc receptor blocker in the U.S and Japan.